Question to the Department of Health and Social Care:

To ask His Majesty's Government when they expect the Medicines and Healthcare products Regulatory Agency to complete its assessment of DCVax-L.

The Medicines and Healthcare Products Regulatory Agency (MHRA) is an executive agency of the Department and regulates medicine, medical devices, and blood components for transfusion in the United Kingdom, with responsibility for ensuring that medicines meet appropriate standards of safety, quality, and efficacy.

Northwest Biotherapeutics has submitted a Marketing Authorization Application to the MHRA for DCVax®-L, an immunotherapy for glioblastoma. The MHRA is unable to comment on applications during the process of review, but the MHRA can confirm that this application is not affected by any historical backlogs, and the agency is assessing all applications rapidly for safety, quality, and efficacy.